Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Author(s): Maria Drakopoulou, Stergios Soulaidopoulos, George Oikonomou, Dimitrios Tousoulis, Konstantinos Toutouzas*

Journal Name: Current Vascular Pharmacology

Volume 18 , Issue 5 , 2020

Become EABM
Become Reviewer

Abstract:

The risk of cardiovascular (CV) disease is increased among patients with systemic autoimmune rheumatic diseases and remains an underserved area of medical need. Although traditional risk factors for CV disease, such as hypertension, smoking, dyslipidemia and obesity contribute to endothelial dysfunction in rheumatoid arthritis (RA), they are not enough on their own to explain the observed excess CV risk. Rather, systemic inflammation seems to play a pivotal role in both disease states. Considering the inflammatory process in autoimmune diseases, scientific interest has focused on recently introduced biologic disease-modifying agents (bDMARDS) such as inhibitors of Tumor Necrosis Factor- α (ΤΝF-α), Interleukins -1 (IL-1) and -6 (IL-6). Despite the widespread use of bDMARDS in RA and other chronic autoimmune inflammatory diseases, their precise impact on CV disease and outcome remains to be elucidated, while prospective randomized control trials assessing their impact on hard CV endpoints are scarce. In this review, we summarize current knowledge concerning the effect of bDMARDs on CV outcome and on the risk of developing CV disease in patients with systemic autoimmune rheumatic diseases.

Keywords: Cardiovascular disease, rheumatoid arthritis, biologic disease-modifying agents, tumor necrosis factor, atherosclerosis.

[1]
Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70(1): 8-14.
[http://dx.doi.org/10.1136/ard.2010.142133 ] [PMID: 21109513]
[2]
Gonzalez A, Maradit Kremers H, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67(1): 64-9.
[http://dx.doi.org/10.1136/ard.2006.059980 ] [PMID: 17517756]
[3]
Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J 2016; 37(22): 1723-32.
[http://dx.doi.org/10.1093/eurheartj/ehv759 ] [PMID: 26843277]
[4]
Zegkos T, Kitas G, Dimitroulas T. Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis 2016; 8(3): 86-101.
[http://dx.doi.org/10.1177/1759720X16643340 ] [PMID: 27247635]
[5]
Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76(1): 17-28.
[http://dx.doi.org/10.1136/annrheumdis-2016-209775 ] [PMID: 27697765]
[6]
Geiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des 2011; 17(29): 3141-54.
[http://dx.doi.org/10.2174/138161211798157658 ] [PMID: 21864263]
[7]
Brånén L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-α reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004; 24(11): 2137-42.
[http://dx.doi.org/10.1161/01.ATV.0000143933.20616.1b ] [PMID: 15345516]
[8]
Ursini F, Leporini C, Bene F, et al. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep 2017; 7(1): 5346.
[http://dx.doi.org/10.1038/s41598-017-05759-2 ] [PMID: 28706194]
[9]
Chen X, Xun K, Chen L, Wang Y. TNF-α, a potent lipid metabolism regulator. Cell Biochem Funct 2009; 27(7): 407-16.
[http://dx.doi.org/10.1002/cbf.1596 ] [PMID: 19757404]
[10]
Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-α therapy. Ann N Y Acad Sci 2010; 1193: 153-9.
[http://dx.doi.org/10.1111/j.1749-6632.2009.05287.x ] [PMID: 20398022]
[11]
Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm 2011; 17(9)(Suppl. B): S14-8.
[http://dx.doi.org/10.18553/jmcp.2011.17.s9-b.S14 ] [PMID: 22073935]
[12]
Lamberg L. A host of novel agents for treating psoriasis, psoriatic arthritis stir interest. JAMA 2003; 289(21): 2779-80.
[http://dx.doi.org/10.1001/jama.289.21.2779 ] [PMID: 12783895]
[13]
Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012; 7(1)e30275
[http://dx.doi.org/10.1371/journal.pone.0030275 ] [PMID: 22272322]
[14]
Hanson M, Gluckman P. Endothelial dysfunction and cardiovascular disease: the role of predictive adaptive responses. Heart 2005; 91(7): 864-6.
[http://dx.doi.org/10.1136/hrt.2004.047381 ] [PMID: 15958346]
[15]
Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. Circulation 2004; 109(25)(Suppl. 1): 31-46.
[http://dx.doi.org/10.1161/01.CIR.0000133442.99186.39 ] [PMID: 15226249]
[16]
Kerekes G, Szekanecz Z, Dér H, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008; 35(3): 398-406.
[PMID: 18203326]
[17]
Wållberg-Jonsson S, Caidahl K, Klintland N, Nyberg G, Rantapää-Dahlqvist S. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand J Rheumatol 2008; 37(1): 1-5.
[http://dx.doi.org/10.1080/03009740701633238 ] [PMID: 18189187]
[18]
Kotani K, Miyamoto M, Ando H. The effect of treatments for rheumatoid arthritis on endothelial dysfunction evaluated by flow-mediated vasodilation in patients with rheumatoid arthritis. Curr Vasc Pharmacol 2017; 15(1): 10-8.
[http://dx.doi.org/10.2174/1570161114666161013113457 ] [PMID: 27739363]
[19]
Sidiropoulos PI, Siakka P, Pagonidis K, et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009; 38(1): 6-10.
[http://dx.doi.org/10.1080/03009740802363768 ] [PMID: 18991190]
[20]
Bosello S, Santoliquido A, Zoli A, et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 2008; 27(7): 833-9.
[http://dx.doi.org/10.1007/s10067-007-0803-y ] [PMID: 18075712]
[21]
Pina T, Corrales A, Lopez-Mejias R, et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. J Dermatol 2016; 43(11): 1267-72.
[http://dx.doi.org/10.1111/1346-8138.13398 ] [PMID: 27062420]
[22]
Avgerinou G, Tousoulis D, Siasos G, et al. Anti-tumor necrosis factor α treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol 2011; 151(3): 382-3.
[http://dx.doi.org/10.1016/j.ijcard.2011.06.112 ] [PMID: 21764467]
[23]
Capria A, De Nardo D, Baffetti FR, et al. Long-term anti-TNF-α treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol 2010; 23(1): 255-62.
[http://dx.doi.org/10.1177/039463201002300123 ] [PMID: 20378011]
[24]
Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012; 25(6): 644-50.
[http://dx.doi.org/10.1038/ajh.2012.12 ] [PMID: 22378036]
[25]
Mäki-Petäjä KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 2006; 114(11): 1185-92.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.601641 ] [PMID: 16952987]
[26]
Tam L-S, Shang Q, Li EK, et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial. J Rheumatol 2012; 39(12): 2267-75.
[http://dx.doi.org/10.3899/jrheum.120541 ] [PMID: 22984272]
[27]
Di Minno MND, Iervolino S, Peluso R, Scarpa R, Di Minno G. Carotid intima-media thickness in psoriatic arthritis. Arterioscler Thromb Vasc Biol 2011; 31: 705-12.
[http://dx.doi.org/10.1161/ATVBAHA.110.214585 ] [PMID: 21212403]
[28]
Del Porto F, Laganà B, Lai S, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46(7): 1111-5.
[http://dx.doi.org/10.1093/rheumatology/kem089 ] [PMID: 17449484]
[29]
Wong M, Oakley SP, Young L, et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68(8): 1277-84.
[http://dx.doi.org/10.1136/ard.2007.086157 ] [PMID: 18930987]
[30]
van Sijl AM, van Eijk IC, Peters MJL, et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis 2015; 74(1): 119-23.
[http://dx.doi.org/10.1136/annrheumdis-2013-203934 ] [PMID: 24092419]
[31]
Weisman MH, Paulus HE, Burch FX, et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford) 2007; 46(7): 1122-5.
[http://dx.doi.org/10.1093/rheumatology/kem033 ] [PMID: 17470434]
[32]
Jacobsson LTH, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32(7): 1213-8.
[PMID: 15996054]
[33]
Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70(4): 576-82.
[http://dx.doi.org/10.1136/ard.2010.129916 ] [PMID: 21109516]
[34]
Carmona L, Descalzo MÁ, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66(7): 880-5.
[http://dx.doi.org/10.1136/ard.2006.067660 ] [PMID: 17324968]
[35]
Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: Results from the QUEST-RA study. Arthritis Res Ther 2008; 10(2): R30.
[PMID: 18325087]
[36]
Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008; 24(2): 469-80.
[http://dx.doi.org/10.1185/030079908X261177 ] [PMID: 18179735]
[37]
Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(12): 3790-8.
[http://dx.doi.org/10.1002/art.22255 ] [PMID: 17136752]
[38]
Barnabe C, Martin B-J, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63(4): 522-9.
[http://dx.doi.org/10.1002/acr.20371 ] [PMID: 20957658]
[39]
Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British society for rheumatology biologics register. Arthritis Rheum 2007; 56(9): 2905-12.
[http://dx.doi.org/10.1002/art.22809 ] [PMID: 17763428]
[40]
Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Askling J. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 2012; 64(1): 42-52.
[http://dx.doi.org/10.1002/art.30654 ] [PMID: 21898355]
[41]
Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006; 55(4): 531-6.
[http://dx.doi.org/10.1002/art.22094 ] [PMID: 16874796]
[42]
Radovits BJ, Popa-Diaconu DA, Popa C, et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2009; 68(8): 1271-6.
[http://dx.doi.org/10.1136/ard.2008.089862 ] [PMID: 18701555]
[43]
Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008; 58(9): 2612-21.
[http://dx.doi.org/10.1002/art.23811 ] [PMID: 18759273]
[44]
Wu JJ, Poon K-YT, Channual JC, Shen AY-J. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012; 148(11): 1244-50.
[http://dx.doi.org/10.1001/archdermatol.2012.2502 ] [PMID: 22911151]
[45]
Wu JJ, Poon K-YT, Bebchuk JD. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. J Drugs Dermatol 2013; 12(8): 899-903.
[PMID: 23986163]
[46]
Bili A, Tang X, Pranesh S, et al. Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66(3): 355-63.
[http://dx.doi.org/10.1002/acr.22166 ] [PMID: 24023053]
[47]
Ljung L, Askling J, Rantapää-Dahlqvist S, Jacobsson L. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014; 16(3): R127.
[http://dx.doi.org/10.1186/ar4584 ] [PMID: 24941916]
[48]
Low AS, Symmons DPM, Lunt M, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2017; 76(4): 654-60.
[http://dx.doi.org/10.1136/annrheumdis-2016-209784 ] [PMID: 28073800]
[49]
Giles JT, Malayeri AA, Fernandes V, et al. Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthritis Rheum 2010; 62(4): 940-51.
[http://dx.doi.org/10.1002/art.27349 ] [PMID: 20131277]
[50]
Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97(14): 1382-91.
[http://dx.doi.org/10.1161/01.CIR.97.14.1382 ] [PMID: 9577950]
[51]
Kotyla PJ, Owczarek A, Rakoczy J, Lewicki M, Kucharz EJ, Emery P. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J Rheumatol 2012; 39(4): 701-6.
[http://dx.doi.org/10.3899/jrheum.110751 ] [PMID: 22337242]
[52]
Çetin S, Mustafa G, Keskin G, Yeter E, Doğan M, Öztürk MA. Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results. Cardiovasc J Afr 2014; 25(4): 168-75.
[http://dx.doi.org/10.5830/CVJA-2014-036 ] [PMID: 25192300]
[53]
Vizzardi E, Cavazzana I, Franceschini F, et al. Left ventricular function in rheumatoid arthritis during anti-TNF-α treatment: a speckle tracking prospective echocardiographic study. Monaldi Arch Chest Dis 2016; 84(1-2): 716.
[http://dx.doi.org/10.4081/monaldi.2015.716 ] [PMID: 27374036]
[54]
Santos RC, Figueiredo VN, Martins LC, et al. Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. Rev Assoc Med Bras (1992) 2012; 58(6): 698-702.
[http://dx.doi.org/10.1590/S0104-42302012000600015] [PMID: 23250099]
[55]
Schau T, Gottwald M, Arbach O, et al. Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type. J Rheumatol 2015; 42(11): 2029-37.
[http://dx.doi.org/10.3899/jrheum.141647 ] [PMID: 26373561]
[56]
Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44(5): 677-80.
[http://dx.doi.org/10.1093/rheumatology/keh610 ] [PMID: 15784627]
[57]
Solomon DH, Rassen JA, Kuriya B, et al. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis 2013; 72(11): 1813-8.
[http://dx.doi.org/10.1136/annrheumdis-2012-202136 ] [PMID: 23155221]
[58]
Curtis JR, Kramer JM, Martin C, et al. Heart failure among younger rheumatoid arthritis and Crohn’s patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 2007; 46(11): 1688-93.
[http://dx.doi.org/10.1093/rheumatology/kem212 ] [PMID: 17938138]
[59]
Morgan CL, Emery P, Porter D, et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford) 2014; 53(1): 186-94.
[http://dx.doi.org/10.1093/rheumatology/ket333 ] [PMID: 24140761]
[60]
Al-Aly Z, Pan H, Zeringue A, et al. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res 2011; 157(1): 10-8.
[http://dx.doi.org/10.1016/j.trsl.2010.09.005 ] [PMID: 21146146]
[61]
Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58(3): 667-77.
[http://dx.doi.org/10.1002/art.23281 ] [PMID: 18311816]
[62]
Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 2007; 27(4): 369-73.
[http://dx.doi.org/10.1007/s00296-006-0215-3 ] [PMID: 17028862]
[63]
Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116(5): 305-11.
[http://dx.doi.org/10.1016/j.amjmed.2003.09.039 ] [PMID: 14984815]
[64]
Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008; 156(2): 336-41.
[http://dx.doi.org/10.1016/j.ahj.2008.02.025 ] [PMID: 18657665]
[65]
Peters MJL, Welsh P, McInnes IB, et al. Tumour necrosis factor alpha blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 2010; 69(7): 1281-5.
[http://dx.doi.org/10.1136/ard.2009.119412 ] [PMID: 19934107]
[66]
Zha AM, Di Napoli M, Behrouz R. Prevention of stroke in rheumatoid arthritis. Curr Neurol Neurosci Rep 2015; 15(12): 77.
[http://dx.doi.org/10.1007/s11910-015-0600-y ] [PMID: 26486791]
[67]
Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008; 59(8): 1090-6.
[http://dx.doi.org/10.1002/art.23935 ] [PMID: 18668583]
[68]
Low ASL, Lunt M, Mercer LK, et al. Association between ischemic stroke and tumor necrosis factor inhibitor therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2016; 68: 1337-45.
[69]
Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1β induces coronary intimal lesions and vasospastic responses in pigs in vivo: the role of platelet-derived growth factor. J Clin Invest 1996; 97: 769-76.
[70]
Isoda K, Sawada S, Ishigami N, et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24(6): 1068-73.
[http://dx.doi.org/10.1161/01.ATV.0000127025.48140.a3 ] [PMID: 15059807]
[71]
Devlin CM, Kuriakose G, Hirsch E, Tabas I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci USA 2002; 99(9): 6280-5.
[http://dx.doi.org/10.1073/pnas.092324399 ] [PMID: 11983917]
[72]
Chamberlain J, Evans D, King A, et al. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol 2006; 168(4): 1396-403.
[http://dx.doi.org/10.2353/ajpath.2006.051054 ] [PMID: 16565512]
[73]
Chamberlain J, Francis S, Brookes Z, et al. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One 2009; 4(4)e5073
[http://dx.doi.org/10.1371/journal.pone.0005073 ] [PMID: 19347044]
[74]
Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160(2): 618-23.
[http://dx.doi.org/10.1084/jem.160.2.618 ] [PMID: 6332168]
[75]
Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 1985; 76(5): 2003-11.
[http://dx.doi.org/10.1172/JCI112200 ] [PMID: 3877078]
[76]
Abbate A, Salloum FN, Van Tassell BW, et al. Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS One 2011; 6(11)e27923
[http://dx.doi.org/10.1371/journal.pone.0027923 ] [PMID: 22140485]
[77]
Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117(14): 3720-32.
[http://dx.doi.org/10.1182/blood-2010-07-273417 ] [PMID: 21304099]
[78]
Buckley LF, Viscusi MM, Tassell B, Van , Abbate A. Interleukin-1 blockade for the treatment of pericarditis. Eur Hear J - Cardiovasc Pharmacother 2018; 4: 46-53.
[79]
Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA 2016; 316(18): 1906-12.
[http://dx.doi.org/10.1001/jama.2016.15826 ] [PMID: 27825009]
[80]
Seropian IM, Toldo S, Van Tassell BW, Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol 2014; 63(16): 1593-603.
[http://dx.doi.org/10.1016/j.jacc.2014.01.014 ] [PMID: 24530674]
[81]
Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction Virginia commonwealth university anakinra remodeling trial [VCU-ART] pilot study. Am J Cardiol 2010; 105(10): 1371-7.
[http://dx.doi.org/10.1016/j.amjcard.2009.12.059 ] [PMID: 20451681]
[82]
Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study. Am J Cardiol 2013; 111(10): 1394-400.
[http://dx.doi.org/10.1016/j.amjcard.2013.01.287 ] [PMID: 23453459]
[83]
Abbate A, Kontos MC, Abouzaki NA, et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol 2015; 115(3): 288-92.
[http://dx.doi.org/10.1016/j.amjcard.2014.11.003 ] [PMID: 25482680]
[84]
Morton AC, Rothman AMK, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J 2015; 36(6): 377-84.
[http://dx.doi.org/10.1093/eurheartj/ehu272 ] [PMID: 25079365]
[85]
Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28(4): 964-71.
[http://dx.doi.org/10.1016/S0735-1097(96)00268-9 ] [PMID: 8837575]
[86]
Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 2003; 107(11): 1486-91.
[http://dx.doi.org/10.1161/01.CIR.0000057810.48709.F6 ] [PMID: 12654604]
[87]
Canada JM, Fronk DT, Cei LF, et al. Usefulness of C-reactive protein plasma levels to predict exercise intolerance in patients with chronic systolic heart failure. Am J Cardiol 2016; 117(1): 116-20.
[http://dx.doi.org/10.1016/j.amjcard.2015.10.020 ] [PMID: 26546248]
[88]
Ikonomidis I, Tzortzis S, Andreadou I, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging 2014; 7(4): 619-28.
[http://dx.doi.org/10.1161/CIRCIMAGING.113.001193 ] [PMID: 24782115]
[89]
Van Tassell BW, Abouzaki NA, Oddi Erdle C, et al. Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study. J Cardiovasc Pharmacol 2016; 67(6): 544-51.
[http://dx.doi.org/10.1097/FJC.0000000000000378 ] [PMID: 26906034]
[90]
Van Tassell BW, Canada J, et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from the recently decompensated heart 36 failure Anakinra response trial (REDHART). Circ Heart Fail 2017; 10e004373
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.117.004373 ] [PMID: 29141858]
[91]
Van Tassell BW, Arena R, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 2014; 113(2): 321-7.
[http://dx.doi.org/10.1016/j.amjcard.2013.08.047 ] [PMID: 24262762]
[92]
Van Tassell BW, Canada J, Buckley L, et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: The diastolic heart failure Anakinra response trial 2 (DHART2). Circulation 2017; 136A17709
[93]
Klein A, Lin D, Cremer P, et al. Efficacy and safety of rilonacept in recurrent pericarditis: a multicenter phase 2 clinical trial. Circulation 2019; 140A12851
[94]
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371(9617): 987-97.
[http://dx.doi.org/10.1016/S0140-6736(08)60453-5 ] [PMID: 18358926]
[95]
Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381(9877): 1541-50.
[http://dx.doi.org/10.1016/S0140-6736(13)60250-0 ] [PMID: 23515142]
[96]
Giles JT, Sattar N, Gabriel SE, et al. Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial. Arthritis Rheumatol 2016. Available from:https://acrabstracts.org/abstract/comparative-cardiovascular-safety-of-tocilizumab-vs-etanercept-in-rheumatoid-arthritis-results-of-a-randomized-parallel-group-multicenter-noninferiority-phase-4-clinical-trial/
[97]
Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58(10): 2968-80.
[http://dx.doi.org/10.1002/art.23940 ] [PMID: 18821691]
[98]
McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015; 74(4): 694-702.
[http://dx.doi.org/10.1136/annrheumdis-2013-204345 ] [PMID: 24368514]
[99]
van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 95-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72: 1496-502.
[http://dx.doi.org/10.1136/annrheumdis-2012-201956] [PMID: 23136242]
[100]
Jin Y, Kang E, Brill G, et al. Comparative cardiovascular safety of abatacept and tumor necrosis factor inhibitors in rheumatoid arthritis patients with and without cardiovascular disease: a population-based cohort study. Ann Rheum Dis 2017; 76: 544.
[101]
Kang EH, Jin Y, Brill G, et al. Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc 2018; 7(3)e007393
[http://dx.doi.org/10.1161/JAHA.117.007393 ] [PMID: 29367417]
[102]
Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum 2016; 46(3): 261-71.
[http://dx.doi.org/10.1016/j.semarthrit.2016.05.014 ] [PMID: 27443588]
[103]
Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99(3): 480-6.
[http://dx.doi.org/10.1160/TH07-11-0685 ] [PMID: 18327395]
[104]
von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100(1): 27-40.
[http://dx.doi.org/10.1161/01.RES.0000252802.25497.b7 ] [PMID: 17204662]
[105]
Massberg S, Brand K, Grüner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196(7): 887-96.
[http://dx.doi.org/10.1084/jem.20012044 ] [PMID: 12370251]
[106]
Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KMJ, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011; 31(2): 153-64.
[http://dx.doi.org/10.1007/s00296-010-1446-x ] [PMID: 20390282]
[107]
Ertenli I, Haznedaroğlu IC, Kiraz S, Celik I, Calgüneri M, Kirazhi S. Cytokines affecting megakaryocytopoiesis in rheumatoid arthritis with thrombocytosis. Rheumatol Int 1996; 16(1): 5-8.
[http://dx.doi.org/10.1007/BF01419947 ] [PMID: 8783415]
[108]
Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8(1): 148-56.
[http://dx.doi.org/10.1111/j.1538-7836.2009.03584.x ] [PMID: 19691485]
[109]
Gasparyan AY, Stavropoulos-Kalinoglou A, Toms TE, Douglas KMJ, Kitas GD. Association of mean platelet volume with hypertension in rheumatoid arthritis. Inflamm Allergy Drug Targets 2010; 9(1): 45-50.
[http://dx.doi.org/10.2174/187152810791292854 ] [PMID: 19906007]
[110]
Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011; 17(1): 47-58.
[http://dx.doi.org/10.2174/138161211795049804 ] [PMID: 21247392]
[111]
Boulman N, Rozenbaum M, Slobodin G, Rosner I. Acute polyarthritis associated with clopidogrel treatment. Isr Med Assoc J 2005; 7(10): 670-1.
[PMID: 16259352]
[112]
Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des 2012; 18(11): 1478-93.
[http://dx.doi.org/10.2174/138161212799504731 ] [PMID: 22364132]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 5
Year: 2020
Published on: 10 August, 2020
Page: [488 - 506]
Pages: 19
DOI: 10.2174/1570161118666200214115532
Price: $65

Article Metrics

PDF: 28
HTML: 1